Elevation of Interleukin 6 in the Dialysate Reflects Peritoneal Stimuli and Deterioration of Peritoneal Function

Fujimori, A.; Naito, Hisao; Miyazaki, Tsuyoshi; Azuma, Masayuki; Hashimoto, Sachie; Horikawa, Seizaburo; Tokukoda, Yasuhide

doi:10.1159/000189373

Cited by 29 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29,30 As a matter of course, a wide number of cytokines and growth factors likely have a role in preserving the complex chronic inflammatory status of the peritoneum. 3,5,28,30,31 Mesothelial cells as well as recruited macrophages are considered to be significantly incorporated into the cytokine network that is associated with peritoneal diseases. 32,33 On the IL-10 and peritoneal fibrosis A Onishi et al other hand, several kinds of MGO-mediated processes have been shown to be implicated in the accelerated productions of TNF-α, IL-1β, and IL-6 in macrophages.…”

Section: Discussionmentioning

confidence: 99%

Attenuation of methylglyoxal-induced peritoneal fibrosis: immunomodulation by interleukin-10

Ōnishi

Akimoto

Urabe

et al. 2015

Laboratory Investigation

View full text Add to dashboard Cite

Peritoneal fibrosis (PF), a serious pathophysiology of peritoneal dialysis (PD), is implicated in various types of chronic inflammation. In the present study, we examined the benefits of interleukin (IL)-10, which exerts anti-inflammatory effects, in an experimental rat model of methylglyoxal (MGO)-induced PF. We injected an adeno-associated virus (AAV) vector encoding rat IL-10 or enhanced green fluorescent protein (GFP) into male Sprague-Dawley rats at 6 weeks of age. Four weeks later, the rats received continuous peritoneal injections of conventional PD fluid (PDF) with MGO for 3 weeks. Then, the peritoneal histology and the expression levels of fibrogenic mediators and proinflammatory cytokines were analyzed. The rats demonstrating persistent IL-10 expression showed significantly reduced fibrous peritoneal thickening compared with those with GFP expression. The infiltration of macrophages, the expression of tumor necrosis factor-α, IL-1β, IL-6, transforming growth factor-β1, Snail, and matrix metalloproteinase 2 genes as well as the proliferation of mesenchymallike mesothelial cells augmented by MGO were all significantly suppressed by IL-10 expression. IL-10 also abrogated the extent of MGO-induced bowel adhesions mimicking a cocoon-like mass. Our findings provide valuable insight into the potential benefit of immunomodulation with IL-10 as one potentially effective therapeutic strategy for preventing the onset of peritoneal injury resulting in PF.

show abstract

Section: Discussionmentioning

confidence: 99%

Attenuation of methylglyoxal-induced peritoneal fibrosis: immunomodulation by interleukin-10

Ōnishi

Akimoto

Urabe

et al. 2015

Laboratory Investigation

View full text Add to dashboard Cite

show abstract

“…Low pH, high osmolarity, high glucose concentration, or the presence of various particles are possible factors [12,33,34]. Our data indicated that a conventional fluid had a greater potential to promote their secretion than the new neutral fluid.…”

Section: Discussionmentioning

confidence: 74%

Short-Term Biological Effects of a New and Less Acidic Fluid for Peritoneal Dialysis

Matsumoto

Sato²,

Miyai³

et al. 2003

Blood Purif

View full text Add to dashboard Cite

Background: Conventional peritoneal dialysates are potentially bioincompatible and seem to be a causative factor for peritoneal sclerosis. Recent studies demonstrated that a new type of dialysate has a positive long-term clinical effect on dialysis patients. Methods: In this study, to elucidate the short-term biological effects of a newly developed dialysate of higher pH on the peritoneal membrane, we assessed macrophage proportions and several markers (inflammatory cytokines, cancer antigen 125 (CA125) and albumin) in spent dialysates before and 2 weeks after the change to the new fluid from a conventional fluid. Results: We found that the use of the new dialysate decreased intraperitoneal levels of inflammatory cytokines, CA125 and albumin associated with the decrease of macrophage populations in dialysis effluents. Conclusion: These observations suggest that a new and less acidic fluid reduces pro-inflammatory potential in the peritoneum, and thus affords better preservation of peritoneal membrane integrity in uremic patients on peritoneal dialysis.

show abstract

“…TGF-β 1 also increases the production of various extracellular matrix and fibrogenesis-associated molecules such as Snail, fibronectin, collagen I, and α-smooth muscle actin (α-SMA) on the peritoneal membrane, leading to peritoneal fibrosis [21–24]. Both glucose-degradation products and advanced glycation end-products have also been reported to promote chronic inflammation characterized by infiltration of macrophages [25,26], which in turn secrete pro-fibrotic cytokines such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6, as well as TGF-β 1 [27–31]. These cytokines induce peritoneal fibrosis by promoting fibroblast proliferation and type I collagen synthesis on the peritoneum [32,33].…”

Section: Mechanism Of Peritoneal Fibrosis Developmentmentioning

confidence: 99%

Nano-sized carriers in gene therapy for peritoneal fibrosisin vivo

Igarashi

Hoshino

Ookawara

et al. 2017

Nano Reviews & Experiments

View full text Add to dashboard Cite

Peritoneal fibrosis is a crucial complication in patients receiving peritoneal dialysis. It is a major pathological feature of peritoneal membrane failure, which leads to withdrawal of peritoneal dialysis. No specific therapy has yet been established for the treatment of peritoneal fibrosis. However, gene therapy may be a viable option, and various nano-sized carriers, including viral and non-viral vectors, have been shown to enhance the delivery and efficacy of gene therapy for peritoneal fibrosis in vivo. This review focuses on the use of nano-sized carriers in gene therapy of peritoneal fibrosis in vivo.

show abstract

Elevation of Interleukin 6 in the Dialysate Reflects Peritoneal Stimuli and Deterioration of Peritoneal Function

Cited by 29 publications

References 0 publications

Attenuation of methylglyoxal-induced peritoneal fibrosis: immunomodulation by interleukin-10

Attenuation of methylglyoxal-induced peritoneal fibrosis: immunomodulation by interleukin-10

Short-Term Biological Effects of a New and Less Acidic Fluid for Peritoneal Dialysis

Nano-sized carriers in gene therapy for peritoneal fibrosisin vivo

Contact Info

Product

Resources

About